Damoctocog alfa pegol
Chemical compound / From Wikipedia, the free encyclopedia
Damoctocog alfa pegol, sold under the brand name Jivi is a recombinant DNA-derived, Factor VIII concentrate used to treat hemophilia A.[5][6]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Jivi |
Other names | BAY94-9027, antihemophilic factor (recombinant), pegylated-aucl |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C7445H11318N1984O2184S69 |
Molar mass | 165774.28 g·mol−1 |
Close
The most common side effects include headache, cough, nausea, and fever.[5]
Damoctocog alfa pegol was approved for medical use in the United States in August 2018,[7] and in the European Union in November 2018.[6][8]